Given that prostate cancer is a highly heterogeneous tumor, somatic mutations of clinicopathologically significant E2Fs, including the E2F1, E2F2, E2F3, E2F5, and E2F6, were further investigated in PCa patients. This evidence concerns the gene E2F5 and prostate cancer.